Talha Badar, Hematology/Oncology Specialist at Mayo Clinic, shared a post on X about a recent article by Mathilde Chanut et al, published in Blood Advances
“New data on asciminib in relapsed/refractory Ph+ ALL and lymphoid blast crisis CML (LBC-CML)!
Published in Blood Advances (July 2025).
1) Dose 200 mg BID
2) 93% previously on ponatinib
27/35 had BCR::ABL1 mutations
- 18 with T315I
- 8 with compound mutations
3) Responses
- 36 evaluable patients → 83% achieved CR/CRi
- Of 23 with MRD data: 57% reached MRD negativity (<0.01% BCR::ABL1)
4) Survival
- Median OS: ~9.8 months
- Median EFS: ~4.9 months
- Longer EFS with combinations vs monotherapy (7.9 vs 4.2 months)”
Title: Asciminib for relapsed or refractory Philadelphia chromosome–positive acute lymphoblastic leukemia
Authors: Mathilde Chanut, Aurélie Cabannes-Hamy, Marie Balsat, Nassim Sahki, Emmanuel Raffoux, Yosr Hicheri, Bruno Lioure, Lucie Laemmel, Thibaut Leguay, Victoria Cacheux, Maria Pilar Gallego-Hernanz, Andrea Pieragostini, Gabrielle Roth-Guepin, Ludovic Gabellier, Nathalie Denizon, Lise Willems, Quentin Cabrera, Sylvain Chantepie, Valérie Coiteux, Claudie Capdupuy, Martin Carré, Antoine Machet, Juliette Lambert, Sandrine Roux, Franck-Emmanuel Nicolini, Nicolas Boissel, Emmanuelle Clappier, Rathana Kim, Philippe Rousselot
Read the Full Article on Blood Advances
More posts featuring Talha Badar.